NCT05438420

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Qurient Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

Conditions

• Esophageal Cancer
• Gastric Cancer
• Hepatocellular Cancer
• Cervical Cancer

Interventions

Type	Name	Description
DRUG	Q702	The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
BIOLOGICAL	Pembrolizumab	Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle

Timeline

• Start date: 2023-01-12
• Primary completion: 2027-12-30
• Completion: 2028-03-30
• First posted: 2022-06-30
• Last updated: 2026-02-24

Locations

7 sites across 2 countries: United States, South Korea

Regulatory

• FDA-regulated drug study